CDK8-IN-13_product_DataBase

Bioactivity	CDK8-IN-13 is a potent, selective and orally active CDK8 inhibitor with an IC50 value of 51.9 nM. CDK8-IN-13 induces Apoptosis. CDK8-IN-13 decreases the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 shows antitumor activity[1].
Invitro	CDK8-IN-13 (compound 43; 1, 2.5, 5, 10 µM; 12 h) 以剂量依赖性方式降低 HCT-116 细胞中 p-STAT1 S727 和 p-STAT5 S726 的表达[1] .CDK8-IN-13 (0, 1, 5, 10 µM; 48 h) 以剂量依赖的方式诱导细胞凋亡[1]。 Cell Proliferation Assay[1] Cell Line:
In Vivo	CDK8-IN-13 (40、80 mg/kg；口服；持续 15 天) 在小鼠体内以剂量依赖性方式抑制肿瘤生长[1]。 Animal Model:
Name	CDK8-IN-13
CAS	918523-75-8
Formula	C14H11N3O
Molar Mass	237.26
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Zhang XX, et al. Discovery of a novel oral type Ⅰ CDK8 inhibitor against acute myeloid leukemia. Eur J Med Chem. 2023 May 5;251:115214.

PeptideDB